Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes
Movement Disorders2021Vol. 36(11), pp. 2663–2669
Citations Over TimeTop 10% of 2021 papers
Cheng Jiang, Franziska Hopfner, Daniela Berg, Michele T. Hu, Andrea Pilotto, Barbara Borroni, Jason J. Davis, George K. Tofaris
Abstract
α-Synuclein and clusterin in L1CAM-immunocaptured serum exosomes is a validated blood test for the molecular stratification of neuronal α-synucleinopathy (ie, Lewy body pathology) versus phenotypically related neurodegenerative movement disorders. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Related Papers
- → Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies(2019)69 cited
- → 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy(2003)47 cited
- → Clusterin regulates transthyretin amyloidosis(2009)16 cited
- → An autopsy case of Alzheimer's disease with a progressive supranuclear palsy overlap(2000)8 cited
- Detection of Clusterin in Saliva on the Various Systemic Condition(2004)